Next-generation Sequencing: Slowly Moving towards the $1,000 Genome
This article was originally published in Start Up
Even if most attempts to read DNA strands in real time appear stalled and the goal of true single-molecule sequencing has, with the notable exception of Helicos, for the most part given way (at least for the time being) in favor of cluster-based approaches with lower data densities, there's still plenty of opportunity for start-ups to advance the field of next-generation sequencing: with microfluidics, nanotechnology, and biochemistries to better enable direct DNA observation and analysis.
You may also be interested in...
Gene sequencing instrument providers are currently at the center of a range of corporate activities: acquisition, partnering, financing. As technology innovation continues, costs decrease, and the pace and scope of clinical genomic studies picks up, the notion of sequencing as the foundation for a clinical diagnostics platform is gaining more support. Delivering value to diagnostics customers ultimately may demand that instrument providers move downstream, involving themselves in data analysis and workflow and even test development, to prime the clinical market.
Say goodbye to the $1000 genome, and even the $100 genome. Thanks to a fledging start-up out of Harvard, there may be an even lower near-term benchmark. Speaking at a meeting in Boston, GnuBio described technology for doing whole-genome sequencing for as little as $30 a pop using an interation of microdroplet technology already in commercial use, out of the same lab.
Highlighting this edition is a pair of privately held genomic sequencing companies that raised funds in new venture rounds.